8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Bristol Myers Squibb raises 2026 outlook after second-quarter revenue growth
Filed with the SEC on · Summarized by InvestorsBot
Bristol Myers Squibb reported second-quarter 2026 revenue of $12.97 billion, up 6% year over year, with non-GAAP EPS of $2.04 and Growth Portfolio revenue rising 15% to $7.6 billion; GAAP EPS was $1.62. On July 30, 2026, the company raised its full-year revenue outlook to approximately $49.0 billion-$50.0 billion from $46.0 billion-$47.5 billion and increased non-GAAP EPS guidance to $6.75-$7.00, while projecting worldwide Eliquis revenue growth of 20%-25% and operating expenses of about $16.5 billion.